Collins Foods (ASX: CKF) - Why We Think CKF Is Entering Its Strongest Earnings Cycle Since Pre-COVID
We believe Collins Foods (ASX: CKF) is entering a multi-year earnings recovery cycle anchored by margin repair in Australia, operational rejuvenation in Europe, clear line-of-sight to double-digit EBITDA growth, and an improving balance sheet that gives management options rather than constraints. The HY26 results demonstrate that CKF is moving decisively out of the inflation shock period that suppressed margins and elevated operating costs between 2022–2024. With commodity and utilities inflation easing, labour efficiencies improving, and price/mix still resilient, we see structural tailwinds forming beneath the company’s operating base.
Bega Group (ASX: BGA): A Turning Point After a Decade of Capital Expansion
Bega Group has evolved from a regional dairy co-operative into a diversified branded food business spanning cheese, spreads and milk beverages, combining defensive staple demand with branded exposure. The investment case now hinges on whether recent operational improvements can translate scale and strong household brands into sustained margin and ROIC expansion. However, with limited product innovation and rising marketing spend largely aimed at defending shelf space, the company’s growth profile remains more defensive than structurally transformative.
With signs of a trend reversal emerging in Treasury Wine Estates (ASX: TWE) shares, what could be the next upside target?
Treasury Wine Estates shows early reversal signs after a downturn, supported by restructuring optimism and stabilising demand. Key upside lies around A$5.30–A$5.70, with further gains possible if momentum holds, though sustained strength is needed to confirm a broader recovery.
Control Bionics (ASX: CBL) - This microcap's share price could explode higher from here!
The small-cap medical-tech company, Control Bionics, has just taken steps that could catapult it far beyond its current size. Its core product, a wearable sensor that translates even the faintest muscle or nerve signals into computer commands, is already approved and helps people with severe physical disabilities communicate and interact. Recently, the company announced that it had integrated a significant tech giant’s brain-computer interface protocol into its devices.
CSL Limited (ASX: CSL) – Structural Quality Re-Asserted
We believe CSL Limited (ASX: CSL) remains one of the highest-quality global healthcare franchises listed on the ASX, with FY25 marking a clear re-acceleration in earnings quality, cash flow conversion, and strategic clarity. While the share price has periodically struggled to reflect this underlying strength, we view CSL as misunderstood rather than mis-executing.
Atomo Diagnostics (ASX: AT1) uptrend is your friend!
Atomo Diagnostics (ASX: AT1) is showing a steady uptrend after a long quiet phase. Rising prices from recent lows, backed by stronger volume, suggest buyers are gradually absorbing supply. This persistent move higher points to improving sentiment and a technically supportive trend for now.